Abiopharma

MEDICUS PHARMA LTD. (MDCXW)

Symbol	MDCXW
Name	MEDICUS PHARMA LTD.
Sector	UNDEFINED
Region	North America
Industry	Pharmaceutical Preparations
Address	300 CONSHOHOCKEN STATE ROAD SUITE 200, CONSHOHOCKEN, Pennsylvania, 19428, United States
Telephone	+1 610 540-7515
Fax	—
Email	—
Website	https://www.medicuspharma.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001997296
Description	Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma. Additional info from NASDAQ: Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.

2026-05-14 20:30

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-14 17:50

New Form 424B3 - Medicus Pharma Ltd. Filed: 2026-05-14 AccNo: 0001062993-26-002638 Size: 445 KB

2026-05-06 11:30

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

2026-05-05 11:55

New Form SCHEDULE 13G/A - Medicus Pharma Ltd. Filed: 2026-05-05 AccNo: 0000950142-26-001279 Size: 11 KB

2026-05-04 17:36

New Form ARS - Medicus Pharma Ltd. Filed: 2026-05-04 AccNo: 0001062993-26-002303 Size: 9 MB

2026-04-29 18:21

New Form 10-K/A - Medicus Pharma Ltd. Filed: 2026-04-29 AccNo: 0001062993-26-002212 Size: 1 MB

2026-04-29 02:20

MDCX attributes changed: Attr: Fin_status N -> D;

2026-04-27 11:30

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

2026-04-24 21:27

(99% Neutral) MEDICUS PHARMA LTD. (MDCX) Announces Business Combination

2026-04-23 18:11

New Form 424B3 - Medicus Pharma Ltd. Filed: 2026-04-23 AccNo: 0001062993-26-002127 Size: 12 KB